CDK4/6 Inhibitors Could Fill Treatment Void for Patients with HR+/HER2- Early Breast Cancer
Joyce O'Shaughnessy, MD, outlines the current role and ongoing research of CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive, HER2-negative early stage breast cancer.
Optimized Therapy Requires More Than Binary Understanding of HER2 Positivity in Metastatic Breast CancerJuly 16th 2022
Neratinib-based combinations, antibody-drug conjugates, and bispecific antibodies represent novel and effective treatment options for patients with pretreated HER2-mutant and HER2-low metastatic breast cancer, but the successful integration of these regimens into care will require further investigation into current definitions of HER2 positivity.
ADCs With Non-Cytotoxic Payloads May Represent the Future of HER2+ Breast Cancer Treatment
The emergence of novel agents like trastuzumab deruxtecan and tucatinib in the HER2-positive breast cancer treatment paradigm have served to markedly improve outcomes for those with this disease, according to Mark Pegram, MD, who added that the future looks bright.
Treatment Strategies Evolve With Increased Disease Specification in HER2+ Breast CancerJuly 15th 2022
Adrienne G. Waks, MD, highlights clinical trials that are studying emerging treatment escalation and de-escalation strategies in early stage HER2-positive breast cancer, elaborates on the future of immunotherapy in this setting, and explains the significance of establishing new biomarkers.
Ovarian Function Suppression Drives Chemotherapy Benefits in Premenopausal HR+/HER2- Breast Cancer
Premenopausal patients with early hormone receptor–positive, HER2-negative breast cancer can benefit from chemotherapy, although it is still debatable whether that benefit stems from the chemotherapy itself or the ovarian function suppression that happens as a result of chemotherapy.
Dr. Kalinsky on Ovarian Function Suppression and Chemotherapy in HR–Positive Breast CancerJuly 14th 2022
Kevin Kalinsky, MD, MS, discusses the relationship between ovarian function suppression and chemotherapy benefits in premenopausal patients with HR–positive breast cancer.
Novel Vaccine Combos Represent a Promising Treatment Approach in Breast CancerJuly 19th 2021
The future of therapeutic vaccines in breast cancer will be dependent on their use in combination with standard anticancer drugs, checkpoint antagonists, and distinct checkpoint inhibitors, Leisha A. Emens, MD, PhD.
Chemoimmunotherapy Shakes Up Metastatic and Early-Stage TNBCJuly 17th 2021
Chemoimmunotherapy combinations have transformed the treatment landscape for patients with triple-negative breast cancer, but balancing potential efficacy with the risk of toxicity with these regimens is critical in both the metastatic and early-stage settings.
Tolaney Spotlights Tailoring Therapy by Risk in HER2+ Breast CancerJuly 16th 2021
By adapting adjuvant therapy based on responses to preoperative therapy, investigators may be able to change long term outcomes for patients with HER2-positive breast cancer, creating a paradigm shift in the space.
Leveraging CDK4/6 Inhibitors in Earlier Settings to Boost Outcomes in HR+ Breast Cancer
Angela DeMichele, MD, MSCE, shares how to utilize available data with CDK4/6 inhibitors in the neoadjuvant and adjuvant settings to optimize outcomes for patients with hormone receptor–positive breast cancer.
Metastatic HER2+ Breast Cancer Treatment Must Move to Personalized ApproachJuly 17th 2020
The optimal sequence of therapies for patients with metastatic HER2-positive breast cancer must be an individualized one, and should be dependent on the presence and/or level of central nervous system disease.